582 related articles for article (PubMed ID: 8859190)
1. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder.
Shiina H; Igawa M; Nagami H; Yagi H; Urakami S; Yoneda T; Shirakawa H; Ishibe T; Kawanishi M
Cancer; 1996 Oct; 78(8):1762-74. PubMed ID: 8859190
[TBL] [Abstract][Full Text] [Related]
2. Relationship of genetic instability with immunoreactivities for p53 protein and proliferating cell nuclear antigen in transitional cell carcinoma of the bladder.
Shiina H; Igawa M; Yagi H; Urakami S; Shirakawa H; Ishibe T
Eur Urol; 1996; 30(1):80-8. PubMed ID: 8854073
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of nm23 protein in transitional cell carcinoma of the bladder.
Shiina H; Igawa M; Urakami S; Shirakawa H; Ishibe T
Br J Urol; 1995 Dec; 76(6):708-13. PubMed ID: 8535713
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder.
Shiina H; Igawa M; Urakami S; Honda S; Shirakawa H; Ishibe T
J Clin Pathol; 1996 May; 49(5):395-9. PubMed ID: 8707954
[TBL] [Abstract][Full Text] [Related]
5. Biological characteristics of inverted papilloma of the urinary bladder.
Urakami S; Igawa M; Shirakawa H; Shiina H; Ishibe T
Br J Urol; 1996 Jan; 77(1):55-60. PubMed ID: 8653317
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the argyrophilic nucleolar organizer region, nuclear DNA content and mean nuclear area in transitional cell carcinoma of bladder using a quantitative image analyzer.
Shiina H; Urakami S; Shirakawa H; Shigeno K; Himeno Y; Mizutani M; Igawa M; Ishibe T
Eur Urol; 1996; 29(1):99-105. PubMed ID: 8821699
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemistry of p53 protein in transitional-cell carcinoma of the bladder using an image analyzer.
Shiina H; Igawa M; Yagi H; Urakami S; Yoneda T; Shirakawa H; Ishibe T
Oncology; 1996; 53(3):233-40. PubMed ID: 8643227
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of immunohistochemically detectable p53 protein in renal cell carcinoma.
Shiina H; Igawa M; Urakami S; Shirakawa H; Ishibe T; Kawanishi M
Eur Urol; 1997; 31(1):73-80. PubMed ID: 9032539
[TBL] [Abstract][Full Text] [Related]
9. p53 and c-jun expression in urinary bladder transitional cell carcinoma: correlation with proliferating cell nuclear antigen (PCNA) histological grade and clinical stage.
Skopelitou A; Hadjiyannakis M; Dimopoulos D; Kamina S; Krikoni O; Alexopoulou V; Rigas C; Agnantis NJ
Eur Urol; 1997; 31(4):464-71. PubMed ID: 9187909
[TBL] [Abstract][Full Text] [Related]
10. Nm23-H1 protein, DNA-ploidy and S-phase fraction in relation to overall survival and disease free survival in transitional cell carcinoma of the bladder.
Alderisio M; Cenci M; Valli C; Russo A; Bazan V; Dardanoni G; Cucciarre S; Carreca I; Macaluso MP; Tomasino RM; Vecchione A
Anticancer Res; 1998; 18(6A):4225-30. PubMed ID: 9891471
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical examinations (Ki67, p53, nm23) and DNA cytophotometry in bladder cancer.
Krause FS; Feil G; Bichler KH
Anticancer Res; 2000; 20(6D):5023-8. PubMed ID: 11326661
[TBL] [Abstract][Full Text] [Related]
12. PCNA and p53 in urinary bladder cancer: correlation with histological findings and prognosis.
Inagaki T; Ebisuno S; Uekado Y; Hirano A; Hiroi A; Shinka T; Ohkawa T
Int J Urol; 1997 Mar; 4(2):172-7. PubMed ID: 9179692
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer.
Lee KE; Lee HJ; Kim YH; Yu HJ; Yang HK; Kim WH; Lee KU; Choe KJ; Kim JP
Jpn J Clin Oncol; 2003 Apr; 33(4):173-9. PubMed ID: 12810831
[TBL] [Abstract][Full Text] [Related]
14. Relationship of serum testosterone level with proliferating cell nuclear antigen and nm23 protein in human prostatic carcinoma tissue.
Shiina H; Igawa M; Shigeno K; Wada Y; Yoneda T; Yagi H; Shirakawa R; Nagasaki M
Oncology; 1997; 54(6):482-9. PubMed ID: 9394845
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of p53 and proliferating cell nuclear antigen (PCNA) in bladder cancer: positive immunostaining and radiosensitivity.
Ogura K; Habuchi T; Yamada H; Ogawa O; Yoshida O
Int J Urol; 1995 Nov; 2(5):302-8. PubMed ID: 8749948
[TBL] [Abstract][Full Text] [Related]
16. DNA content and proliferation activity in superficial transitional cell carcinoma of the bladder.
Pantazopoulos D; Ioakim-Liossi A; Karakitsos P; Aroni K; Kakoliris S; Kanavaros P; Kyrkou KA
Anticancer Res; 1997; 17(1B):781-6. PubMed ID: 9066620
[TBL] [Abstract][Full Text] [Related]
17. Expression of the cyclin-dependent kinase inhibitor p27 in transitional cell bladder cancers: is it a good predictor for tumor behavior?
Doganay L; Altaner S; Bilgi S; Kaya E; Ekuklu G; Kutlu K
Int Urol Nephrol; 2003; 35(2):181-8. PubMed ID: 15072490
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
[TBL] [Abstract][Full Text] [Related]
19. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of nuclear p53 and tumor progression in bladder cancer.
Esrig D; Elmajian D; Groshen S; Freeman JA; Stein JP; Chen SC; Nichols PW; Skinner DG; Jones PA; Cote RJ
N Engl J Med; 1994 Nov; 331(19):1259-64. PubMed ID: 7935683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
